Highest-materiality recent filing
RFAC extends SPAC deadline to Aug 2026; ~$71.6M redeemed from trust
Shareholders approved up to 9 monthly extensions from Nov 15, 2025 to Aug 15, 2026 for business combination.
RF Acquisition Corp II to merge with Nanyang Biologics in $1.5B SPAC deal; NYB to list on Nasdaq
Business Combination Agreement signed Oct 2, 2025; RFAC II will merge into PubCo, then amalgamate with Nanyang.
Tse Meng Ng resigns from RF Acquisition Corp II audit committee, stays on board
Resignation from audit committee effective May 21, 2025.
RF Acquisition Corp II appoints Tuan Lee Low to board as Class I director
Tuan Lee Low appointed as Class I director, term expiring at 2028 annual meeting.
RF Acquisition Corp II units to separate into ordinary shares and rights on July 5, 2024
Holders of 11,500,000 units may elect separate trading of ordinary shares and rights beginning July 5, 2024.
RF Acquisition Corp II completes $100M IPO and overallotment; trust holds $115.6M
IPO of 10,000,000 units at $10.00 per unit generated $100M gross proceeds.
RF Acquisition Corp II closes $100M IPO; $100.5M placed in trust
Priced 10M units at $10.00 each; gross proceeds $100M; units trade on Nasdaq under RFAIU.
On May 1, 2025, Tuan Lee Low was appointed to the board of directors (the “Board”) of RF Acquisition Corp II (the “Company”) as a Class I director
Max materiality 0.85 · Median 0.50 · Most common event other_material